GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases

<p>Data presented at the 7th Annual Antifibrotic Drug Development (AFDD) Summit Company’s lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells early in the inflammatory cascade to prevent cytokine release, cellular infiltration, and interrupts disease progression at the source Daily oral administration of GRI-0621 (a human equivalent [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/gri-bio-presents-data-supporting-innovative-pipeline-of-nkt-cell-modulators-for-the-treatment-of-high-value-inflammatory-fibrotic-and-autoimmune-diseases/">GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>